Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Blood Cells, Molecules & Diseases

• Publication date

  2005-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.BCMD.2004.11.006PMID 15727903
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.

  2003cited by this paper
• Primary brain tumours in adults.

  2003cited by this paper
• Primary brain tumours in adults.

  2003cited by this paper
• Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity.

  2003cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

  2002cited by this paper
• Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells

  2001cited by this paper
• BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance.

  2001cited by this paper
• Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

  2000cited by this paper
• Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.

  2000cited by this paper
• A New Model of Thermal Inactivation and its Application to Clonogenic Survival Data for WiDr Human Colonic Adenocarcinoma Cells

  2000cited by this paper
• c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF.

  1999cited by this paper
• In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.

  1999cited by this paper
• Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

  1996cited by this paper
• Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro.

  1995cited by this paper
• Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor.

  1994cited by this paper
• Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant

  1993cited by this paper
• Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops.

  1992cited by this paper
• Receptors for platelet derived growth factor in human glioma cell lines and influence of suramin on cell proliferation

  1991cited by this paper
• Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines.

  1991cited by this paper

• Pharmacological PDGFRβ inhibitors imatinib and sunitinib cause human brain pericyte death in vitro.

  2022cites this paper
• Angiogenesis and Its Targeting in Glioblastoma with Focus on Clinical Approaches

  2022cites this paper
• AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer

  2020cites this paper
• Overcoming the Blood–Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours

  2020cites this paper
• Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma

  2019cites this paper
• Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma

  2019cites this paper
• Innovative Therapeutic Approaches to Fight Glioblastoma

  2019cites this paper
• Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines

  2019influential citation
• The biology and mathematical modelling of glioma invasion: a review

  2017cites this paper
• Silencing platelet-derived growth factor receptor-β enhances the radiosensitivity of C6 glioma cells in vitro and in vivo.

  2017cites this paper
• In cancer cell lines inhibition of SCF/c-Kit pathway leads to radiosensitization only when SCF is strongly over-expressed

  2017cites this paper
• Mindfulness Meditation for Fibromyalgia: Mechanistic and Clinical Considerations

  2017cites this paper
• Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors

  2017cites this paper
• Pharmaceutical development of the ISOL technique for the production of radionuclides and their applications in targeted radionuclide therapy

  2017cites this paper
• Targeted Therapy for Hepatocellular Carcinoma.

  2016cites this paper
• Resistance of Brain Tumours to Small-Molecule-Targeted Therapies: Lessons from Various Cancer Types

  2016cites this paper
• Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells

  2016cites this paper
• Investigation of imatinib loaded surface decorated biodegradable nanocarriers against glioblastoma cell lines: Intracellular uptake and cytotoxicity studies.

  2016cites this paper
• Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

  2015cites this paper
• Role of the anti-glioma drug AT13148 in the inhibition of Notch signaling pathway.

  2015cites this paper
• 血小板源生长因子家族在非小细胞肺癌中的研究进展

  2014cites this paper
• Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells

  2014cites this paper
• Mesenchymal stem cells are sensitive to treatment with kinase inhibitors and ionizing radiation

  2014cites this paper
• Targeting the PDGF signaling pathway in tumor treatment

  2013cites this paper
• Assessment of Tracer 99mTc(V)-DMSA Uptake as a Measure of Tumor Cell Proliferation In Vitro

  2013cites this paper
• The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines

  2013cites this paper
• Enhancing radiation therapy for patients with glioblastoma

  2013cites this paper
• The treatment of glioblastomas: a systematic update on clinical Phase III trials.

  2013cites this paper
• Targeting the PDGF signaling pathway in tumor

  2013cites this paper
• Chemotherapeutic Agent for Glioma

  2013cites this paper
• Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas

  2012cites this paper
• Effects of Chemotherapeutics on Organotypic Corticostriatal Slice Cultures Identified by A Panel of Fluorescent and Immunohistochemical Markers

  2012influential citation
• Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas

  2012cites this paper
• Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.

  2012cites this paper
• Novel therapies for high-grade gliomas: A vision for future

  2012cites this paper
• The role of platelet-derived growth factor in radiation injury to the lower urinary tract

  2011cites this paper
• Chemotherapie bei Gliomen

  2011cites this paper
• Targeted therapy for malignant gliomas: state-of-the-art

  2011cites this paper
• Pathway inhibition: emerging molecular targets for treating glioblastoma.

  2011cites this paper
• Sensitivity to and functional effects of tricyclic agents on glioma: an immunohistochemical and in vitro study

  2011cites this paper
• In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation

  2010cites this paper
• In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells

  2010cites this paper
• In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells.

  2010cites this paper
• Determination of CD117 Expression in Glial Tumors and Its Comparison between High Grade and Low Grade Tumors

  2010cites this paper
• - 1In Vitro Effects of Imatinib Mesylate on Radiosensitivity and Chemosensitivity of Breast Cancer Cells

  2010cites this paper
• Glioma stem cell signaling: therapeutic opportunities and challenges

  2010cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 527 Combination Therapies Targeting PDGF and VEGF Signaling Pathways in Solid Tumors

  2010cites this paper
• Experimental approaches for the treatment of malignant gliomas.

  2010cites this paper
• Novel Therapies for Brain Tumors

  2009cites this paper
• Influence of imatinib mesylate on radiosensitivity of astrocytoma cells.

  2009cites this paper
• Current concepts and newer developments in the treatment of malignant gliomas.

  2009cites this paper
• Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

  2009cites this paper
• Local Delivery of Poly Lactic-co-glycolic Acid Microspheres Containing Imatinib Mesylate Inhibits Intracranial Xenograft Glioma Growth

  2009cites this paper
• Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment

  2009influential citation
• Anti-apoptosis mechanisms in malignant gliomas.

  2008cites this paper
• Growth inhibition by STI 571 in combination with radiation in human chronic myelogenous leukemia K 562 cells

  2008cites this paper
• ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.

  2008cites this paper
• Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells

  2008cites this paper
• Down-regulation of Wilms’ tumor 1 expression in glioblastoma cells increases radiosensitivity independently of p53

  2007cites this paper
• Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate.

  2007cites this paper
• A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation

  2007cites this paper
• Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells

  2007cites this paper
• Efficacy of Different Regimens of Adjuvant Radiochemotherapy for Treatment of Glioblastoma

  2007cites this paper
• Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.

  2007cites this paper
• Receptor tyrosine kinases as therapeutic targets in malignant glioma.

  2007cites this paper
• A Radioprotective Effect of Imatinib (Gleevec®) in Human Squamous Carcinoma Cells

  2007influential citation
• The role of PDGF in radiation oncology

  2007cites this paper
• Emerging Role of Platelet-Derived Growth Factor Receptor-β Inhibition in Radioimmunotherapy of Experimental Pancreatic Cancer

  2007cites this paper
• Inhibiting kinases in malignant gliomas

  2007cites this paper
• Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future

  2006cites this paper
• Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity

  2006influential citation
• Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.

  2006cites this paper
• Immunohistochemical Evaluation of KIT Expression in Sarcomas of the Gynecologic Region

  2006cites this paper
• Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment

  2006cites this paper
• Glioma oncogenesis and animal models of glioma formation.

  2006cites this paper
• Enhancement of radiation sensitivity, delay of proliferative recovery after radiation and abrogation of MAPK (p44/42) signaling by imatinib in glioblastoma cells.

  2006cites this paper
• Radiosensitizers in Brain Cancer

  2006cites this paper
• Antiangiogenic and radiotherapy for cancer treatment.

  2006cites this paper
• New approaches to the chemotherapy of glioblastoma: investigations on doxorubicin nanoparticles, inhibition of PDGF receptors and kinesin Eg5, with emphasis on confocal laser-scanning microscopy

  2006cites this paper
• The Expression and Function of Wilms' Tumor 1 in Malignant Glioma

  2006cites this paper
• Review Antiangiogenic and radiotherapy for cancer treatment

  2006cites this paper
• Role of ABC transporters in the chemoresistance of human gliomas.

  2006cites this paper
• Imatinib may be useful in the management of patients with glioblastoma.

  2005cites this paper
• Retrospective analysis of re-irradiation in malignant glioma: a single-center experience

  2005cites this paper
• Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series.

  2005cites this paper
• Tyrosine kinases as targets for cancer therapy.

  2005cites this paper
• The Use of Tyrosine Kinase Inhibitors in Modifying the Response of Tumor Microvasculature to Radiotherapy

  2005cites this paper